Vaccines Updates and Statements

07.28.2021

Pfizer and BioNTech Share Detailed Update to the Results from 6 Month Safety and Efficacy Data Analysis of Landmark COVID-19 Vaccine Study

07.16.2021

U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine

07.08.2021

Newly Published Expert Opinion Article Details Evidence for Classifying Aging Immune System as a High-Risk Condition for Pneumococcal Vaccine Policy

07.08.2021

Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant

04.09.2021

Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents

03.03.2021

Pfizer-BioNTech’s COVID-19 Vaccine Arrives in Rwanda

02.19.2021

President Biden Visits Pfizer’s Kalamazoo Manufacturing Facility

02.08.2021

Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants

02.01.2021

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

01.20.2021

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

01.08.2021

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

12.17.2020

Pfizer COVID-19 Vaccine Production and Distribution Working Well